Corticosteroids in MAC Infection: Use Only as Adjunctive Therapy in Refractory Cases
Corticosteroids should NOT be routinely given to patients with MAC infection, but can be considered as adjunctive therapy specifically for patients with disseminated MAC who have refractory symptoms despite adequate antimycobacterial treatment.
Primary Concern: Corticosteroids as a Risk Factor
The evidence clearly demonstrates that corticosteroid use is a significant risk factor for developing MAC infection in the first place. Patients receiving long-term corticosteroids are at increased risk for developing pulmonary MAC disease 1, and higher corticosteroid doses at the time of initiating biologic agents are associated with significantly increased NTM complications 2. This creates a fundamental tension: steroids can worsen or precipitate MAC infection, yet may provide symptomatic benefit in specific refractory cases.
When Corticosteroids May Be Considered
Specific Clinical Scenario: Refractory Disseminated MAC in AIDS
The only evidence supporting corticosteroid use comes from small retrospective studies in AIDS patients with disseminated MAC who had:
- Progressive symptoms despite combination antimycobacterial therapy
- Persistent fever, night sweats, and weight loss
- Already receiving appropriate multi-drug MAC treatment
In these highly selected cases:
- Low-dose oral corticosteroids (typically dexamethasone 2 mg/day or equivalent) as adjunctive therapy resulted in rapid symptom improvement in 11/12 patients 3
- Patients experienced weight gain (12-50% increase, P<0.03), fever reduction, and improved well-being 4
- Serum albumin increased and alkaline phosphatase decreased 4
Critical Caveats and Pitfalls
The risks are substantial:
- New opportunistic infections developed in 7/12 patients during corticosteroid therapy 3
- While causality couldn't be definitively established due to severe immunocompromise, this represents a 58% rate of new infections
- Mortality can be significant - 22.2% in NTM-complicated patients on biologics/steroids versus 2.6% without NTM 2
- MAC disease associated with corticosteroid use shows atypical radiographic findings and poor treatment response (only 33% sputum conversion rate) 1
Algorithmic Approach
Step 1: Is the patient on guideline-based MAC therapy?
- If NO → Optimize antimycobacterial regimen first (macrolide + ethambutol + rifamycin) 5
- If YES → Proceed to Step 2
Step 2: Does the patient have disseminated MAC with refractory symptoms?
- If NO → Do NOT use corticosteroids
- If YES → Consider low-dose corticosteroids as adjunctive therapy only
Step 3: If considering corticosteroids:
- Use lowest effective dose (e.g., dexamethasone 2 mg/day)
- Continue full antimycobacterial therapy
- Monitor closely for new opportunistic infections
- Reassess frequently for benefit versus risk
Contraindications to Corticosteroid Use
Absolute contraindications:
- Newly diagnosed MAC without adequate antimycobacterial coverage
- Pulmonary MAC in non-AIDS patients (no supporting evidence)
- Macrolide-resistant MAC (requires intensified therapy, not immunosuppression)
Relative contraindications:
- Any MAC patient not yet on appropriate multi-drug therapy
- Patients with other active opportunistic infections
- Those requiring high-dose corticosteroids for other conditions (significantly increases MAC risk) 2
The Bottom Line
The 2020 ATS/ERS/ESCMID/IDSA guidelines 5 do not recommend corticosteroids for MAC treatment. The only supporting evidence comes from small, dated studies in a very specific population (AIDS patients with disseminated, refractory disease). In real-world practice, corticosteroids should be avoided in MAC patients unless dealing with disseminated disease that has failed to respond symptomatically to adequate antimycobacterial therapy, and even then, only with extreme caution and close monitoring for secondary infections.